News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Treatment-experienced people news

Show

From To
Resistance
Second major study shows rise in drug resistance is not increasing AIDS or death risk

The development of resistance to antiretroviral drugs does not increase the risk of HIV disease progression or death, according to an American study published in

Published
05 August 2004
By
Liz Highleyman
Treatment-experienced people
Two-year data continue to show promise for T-20

In the second year of follow-up, patients injecting the fusion inhibitor enfuvirtide (T-20, Fuzeon) continue to exhibit viral suppression with no new adverse effects, according

Published
13 July 2004
By
Christopher Gadd
Treatment-experienced people
Boosted dual PI salvage regimen safe, effective but high pill burden an issue

A dual protease inhibitor regimen of saquinavir and amprenavir boosted with low-dose ritonavir appears safe and effective as salvage therapy, as long as therapeutic drug

Published
05 July 2004
By
Edwin J. Bernard
Resistance
Stopping NNRTIs in drug-resistant patients does not alter viral loads or CD4 cell counts

Withdrawal of non-nucleoside reverse transcriptase inhibitors (NNRTIs) from the antiretroviral drug combination of patients with resistance to this drug class does not lead to viral

Published
28 June 2004
By
Christopher Gadd
Resistance
Treatment failure due to drug resistance not a major cause of death

A Canadian study has found that treatment failure due to drug resistance did not significantly contribute to the mortality of people with HIV in British

Published
25 June 2004
By
Edwin J. Bernard
HIV treatment
Tipranavir access expanded, but doctors warned on double boosted PI regimens

Boehringer-Ingelheim has announced that its new experimental protease inhibitor tipranavir is to be made available to a wider number of patients in the United Kingdom. The

Published
15 June 2004
By
Keith Alcorn
Resistance
Boosted PIs superior to no PIs as salvage therapy in highly PI-experienced

A small Italian study comparing boosted protease inhibitor (PI) and PI-sparing salvage regimens in the highly PI-experienced has found the former superior in preserving CD4

Published
24 April 2004
By
Edwin J. Bernard
Treatment-experienced people
Gilead abandons research on salvage drug

Gilead Sciences today announced that it has decided to abandon its research programme to develop the experimental nucleoside analogue amdoxovir (DAPD). Rights to develop the

Published
28 January 2004
By
Keith Alcorn
← Prev1...1213141516Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.